Giovanna Sarno

Giovanna Sarno

Auto-generated profile, based on publicly available information

Giovanna Sarno

Department of Medical Sciences, Cardiology, Uppsala University Hospital, Uppsala University, Uppsala, Sweden

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2014 in JACC
Verified
Journal Article
Closed access
GSGiovanna Sarno
Giovanna Sarno
BLBo Lagerqvist
Bo Lagerqvist
JNJohan Nilsson
Johan Nilsson
OFOle Frobert
Ole Frobert
KHKristina Hambraeus
Kristina Hambraeus
SJStefan K. James
Stefan K. James

1 April 2020 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
Angelo SilverioAngelo Silverio
Angelo Silverio
SBSergio Buccheri
Sergio Buccheri
DVDimitrios Venetsanos
Dimitrios Venetsanos
JAJoakim Alfredsson
Joakim Alfredsson
BLBo Lagerqvist
Bo Lagerqvist
GSGiovanna Sarno
Giovanna Sarno

22 May 2017 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
GSGiovanna Sarno
Giovanna Sarno
BLBo Lagerqvist
Bo Lagerqvist
GOGöran Olivecrona
Göran Olivecrona
CVChristoph Varenhorst
Christoph Varenhorst
MDMikael Danielewicz
Mikael Danielewicz
SJStefan James
Stefan James

7 January 2011 in The International Journal of Cardiovascular Imaging
Verified
Journal Article
Open access
PDF file
GSGiovanna Sarno
Giovanna Sarno
NBNico Bruining
Nico Bruining
YOYoshinobu Onuma
Yoshinobu Onuma
Scot GargScot Garg
Scot Garg
SBSalvatore Brugaletta
Salvatore Brugaletta
PSPatrick Serruys
Patrick Serruys
The aim of this study was to describe vaso-reactivity (by Acetylcholine and Methergine tests) at 2 year follow-up in parallel with the individual changes in the echogenicity characteristics of the polymer struts of the everolimus eluting bioresorbable vascular scaffold (BVS), from post-treatment to 2 year follow-up, in patients enrolled in the ABSORB Cohort A study. Intravascular ultrasound assessment was performed with a phased array catheter (EagleEye, Volcano Corporation, Cordova, CA, USA) with automated pullback at 0.5 mm per second. The % ratio at 6 months and 2 years [(Scaffold Area post PCI- Lumen Area)/Scaffold Area post PCI] was calculated as a measure of scaffold shrinkage. The % change of hyperechogenicity was defined as: ([post-procedural hyperechogenicity] − [2 year follow up hyperechogenicity])/[post-procedural hyperechogenicity]) × 100. The vasomotion test with intracoronary acetylcholine (10−6 M) or intravenous methergine (0.4 mg) was performed at 2 years. Overall nine patients received all these analyses and were enrolled in the present analysis. A 50–96% reduction in hyperechogenicity was observed between baseline and 2 years, which corresponded to a change in vasoreactivity between 2 and 22%. A vasoconstriction of the scaffolded segment was observed in the 5 patients, who underwent the methergine test, with a mean decrease in lumen diameter after methergine of 9 ± 7% (P = 0.06), while vasodilatation occurred in the 4 patients who underwent the acetylcholine test with a mean increase in lumen diameter after acetylcholine of 8 ± 5% (P = 0.125). Bioresorption of the BVS is accompanied by re-establishment of both endothelial and non-endothelial dependent vasomotion.

4 May 2019 in Heart
Verified
Journal Article
Open access
PDF file
DLDaniel Lindholm
Daniel Lindholm
GSGiovanna Sarno
Giovanna Sarno
DEDavid Erlinge
David Erlinge
BSBodil Svennblad
Bodil Svennblad
LHLars Pål Hasvold
Lars Pål Hasvold
SJStefan K James
Stefan K James
Objective In patients with myocardial infarction (MI), risk factors for bleeding and ischaemic events tend to overlap, but the combined effects of these factors have scarcely been studied in contemporary real-world settings. We aimed to assess the combined associations of established risk factors using nationwide registries. Methods Using the Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies registry, patients with invasively managed MI in 2006–2014 were included. Six factors were assessed in relation to cardiovascular death (CVD)/MI/stroke, and major bleeding: age ≥65, chronic kidney disease, diabetes, multivessel disease, prior bleeding and prior MI. Results We studied 100 879 patients, of whom 20 831 (20.6%) experienced CVD/MI/stroke and 5939 (5.9%) major bleeding, during 3.6 years median follow-up. In adjusted Cox models, all factors were associated with CVD/MI/stroke, and all but prior MI were associated with major bleeding. The majority (53.5%) had ≥2 risk factors. With each added risk factor, there was a marked but gradual increase in incidence of the CVD/MI/stroke. This was seen also for major bleeding, but to a lesser extent, largely driven by prior bleeding as the strongest risk factor. Conclusions The majority of patients with MI had two or more established risk factors. Increasing number of risk factors was associated with higher rate of ischaemic events. When excluding patients with prior major bleeding, bleeding incidence rate increased only minimally with increasing number of risk factors. The high ischaemic risk in those with multiple risk factors highlights an unmet need for additional preventive measures.

21 December 2010 in The International Journal of Cardiovascular Imaging
Verified
Journal Article
Open access
PDF file
ZSZhu Jun Shen
Zhu Jun Shen
SBSalvatore Brugaletta
Salvatore Brugaletta
HGHéctor M. Garcia Garcia
Héctor M. Garcia Garcia
JLJurgen Ligthart
Jurgen Ligthart
JGJosep Gomez-Lara
Josep Gomez-Lara
PSPatrick Serruys
Patrick Serruys
The purpose of this article is to investigate the prevalence of plaque prolapse (PP) after Xience V and Taxus Liberte stent implantation. During the study period 2006–2007, 200 consecutive patients underwent coronary revascularization for de novo lesions and received an intravascular ultrasound (IVUS) post-stenting evaluation, (n = 124 patients with Taxus Liberte and n = 76 with Xience V) (227 stent segments). Cross-sectional and longitudinal 3D IVUS images were analyzed in a blind fashion, evaluating the prevalence of PP and calculating its depth and angle. The angulation degree of the coronary artery at the lesion site pre-stent implantation was also evaluated by angiography. The prevalence of PP was 23.9% in Xience V versus 38.1% in Taxus Liberte (P = 0.025). The depth and angle of PP were greater in Taxus Liberte stent than Xience V stent (0.4 ± 0.1 mm versus 0.5 ± 0.2 mm, P = 0.004; and 32.0 ± 8.9° versus 44.6 ± 27.6°, P = 0.044, respectively). The angulation degree of the coronary artery at the lesion site was higher in presence of plaque prolapse than in its absence (48.2 ± 29.3° vs. 38.2 ± 28.1°, P = 0.013). By multivariate analysis, stent type was independently associated with incidence of plaque prolapse. Xience V stent has less plaque prolapse than Taxus Liberte stent. Stent design may play a role in the prevalence of plaque prolapse.